J&J reports patient findings from Sjögren’s drug study

Seeking Alpha · November 8, 2026, 19:36 UTC

Tickers: $JNJ

Topics: clinical trial results drug development Sjögren's syndrome

Read the full article at Seeking Alpha

Part of the story Palvella Reports Q3 2026 Financial Results and FDA Priority Review for QTORIN (6 articles)

More World news

Team, Inc. (TISI) Reports Q3 2026 Results Amid Turnaround Deferrals and Geopolitical Disruptions Motley Fool · November 12, 2026, 19:44 UTC
Berkshire Hathaway Stock Reaches Record Levels Amid CEO Greg Abel's Leadership Motley Fool · November 12, 2026, 19:45 UTC
Data I/O Reports Q3 2026 Results Amid V-TEK Acquisition and Automotive Softness Motley Fool · November 12, 2026, 19:45 UTC
Google Unveils Gemini 4 Hydrogen AI Model Optimized for Coding Efficiency Seeking Alpha · November 12, 2026, 19:44 UTC
CMS Announces Final Valuations and Reimbursement Rates for New ESD CPT Codes PR Newswire · November 12, 2026, 19:43 UTC
IRS Announces 2027 Retirement Contribution Limits and Social Security COLA Increase Motley Fool · November 12, 2026, 19:37 UTC
Yesway Reaffirms 2026 EBITDA Guidance and Outlines Texas Allsup’s Conversion Timeline Seeking Alpha · November 12, 2026, 19:40 UTC
Boost Run Reports 496% Year-Over-Year Revenue Growth in Q3 2026 Seeking Alpha · November 12, 2026, 19:40 UTC
AiPrise Launches Token Sharing Infrastructure to Streamline Compliance Verification PR Newswire · November 12, 2026, 19:39 UTC
Barclays Upgrades Steel Producers Cleveland-Cliffs and Reliance Amid Market Selloff Seeking Alpha · November 12, 2026, 19:32 UTC